China SXT Pharmaceuticals (NASDAQ:SXTC) Trading Down 11.3% – Here’s Why

Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) dropped 11.3% on Tuesday . The stock traded as low as $2.33 and last traded at $2.36. 119,446 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 1,637,487 shares. The stock had previously closed at $2.66.

Analyst Ratings Changes

A number of research firms have commented on SXTC. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings cut shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, August 31st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

China SXT Pharmaceuticals Trading Up 11.9%

The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $43.08 and a 200-day moving average of $115.23.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings data on Wednesday, July 1st. The company reported $6.84 earnings per share for the quarter. The company had revenue of $0.26 million for the quarter.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.